<html><head></head><body><h1>Lidocaine (Systemic)</h1><p class="drug-subtitle"><b>Class:</b> Class Ib Antiarrhythmics<br/>
<b>Molecular Formula:</b> C<sub>25</sub>H<sub>28</sub>N<sub>6</sub>O<sub>3</sub>S•½C<sub>4</sub>H<sub>4</sub> O<sub>4</sub><br/>
<b>CAS Number:</b> 6108-05-0<br/></p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>Antiarrhythmic agent; an amide-type local anesthetic, class Ib agent.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Lidocaine (Systemic)</h2><h3>Ventricular Arrhythmias</h3><p>Alternative to other antiarrhythmic drugs (e.g., amiodarone, procainamide, sotalol) for the acute treatment of life-threatening ventricular arrhythmias such as those that occur following MI or during cardiac manipulative procedures such as cardiac surgery.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;500&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Used during cardiac arrest for treatment of refractory (i.e., resistant to CPR, defibrillation, and a vasopressor [epinephrine]) VF or pulseless VT.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Considered an alternative to amiodarone for this use in current ACLS guidelines in adults; in pediatric patients, current evidence supports use of either amiodarone or lidocaine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;402&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alternative to other antiarrhythmic agents or synchronized electrical cardioversion in the treatment of hemodynamically stable monomorphic VT; however, other agents (e.g., procainamide, sotalol, amiodarone) preferred.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Status Epilepticus</h3><p>Treatment of status epilepticus†, as a last resort.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Lidocaine (Systemic) Dosage and Administration</h2><h3>General</h3><ul>
<li>
<p><i>Solutions containing epinephrine must not be used to treat arrhythmias.</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Adjust dosage carefully according to individual requirements and response;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; constant ECG monitoring is recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Terminate infusion as soon as the basic cardiac rhythm appears to be stable or at the earliest sign of toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Immediately stop infusion if signs of excessive cardiac depression occur (e.g., prolongation of PR interval and QRS complex, appearance or aggravation of arrhythmias).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Infusions continued for &gt;24 hours should be rarely necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p><i>Solutions containing epinephrine must not be used to treat arrhythmias.</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjust dosage carefully according to individual requirements and response;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; constant ECG monitoring is recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Terminate infusion as soon as the basic cardiac rhythm appears to be stable or at the earliest sign of toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Immediately stop infusion if signs of excessive cardiac depression occur (e.g., prolongation of PR interval and QRS complex, appearance or aggravation of arrhythmias).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Infusions continued for &gt;24 hours should be rarely necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>Administer IV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Has been administered IM (IM formulation no longer commercially available in the US).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Also has been administered via endotracheal tube† or by intraosseous (IO) injection† during cardiac resuscitation when IV administration is not possible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;400&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Although endotracheal† administration also is possible, IV or IO† administration is preferred because of more predictable drug delivery and pharmacologic effect.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Absorption under Pharmacokinetics.)</p><p>For solution and drug compatibility information, see Compatibility under Stability.</p><p>Administer as a bolus IV injection for initial treatment of ventricular arrhythmias.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Maintenance IV infusions may be required to maintain normal sinus rhythm if oral antiarrhythmic therapy is not feasible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Injections containing preservatives should <i>not</i> be given IV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not introduce additives into solutions of lidocaine in 5% dextrose, since dosage is titrated to response.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do <i>not</i> add to blood transfusion assemblies.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not use commercially available solutions of lidocaine in 5% dextrose in series connections with other plastic containers; such use could result in air embolism.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer IV bolus dose at a rate of 25–50 mg/minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;500&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer maintenance infusions at a rate of 1–4 mg/minute (14–57 mcg/kg per minute) in adults or 10–50 mcg/kg per minute in pediatric patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For other populations, see Special Populations under Dosage and Administration.</p><p>For endotracheal administration in adults, dilute dose in 5–10 mL of 0.9% sodium chloride injection or sterile water.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In pediatric patients, flush with 5 mL of 0.9% sodium chloride injection after dose is administered.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dilution in sterile water may increase absorption of lidocaine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Available as lidocaine hydrochloride; dosage is expressed in terms of the salt.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Controlled clinical studies to establish pediatric dosing have not been performed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;100&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some clinicians have suggested initial dose of 0.5–1 mg/kg as a rapid IV injection (i.e., bolus); dose may be repeated according to patient response, up to a maximum total dose of 3–5 mg/kg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Maintenance infusion of 10–50 mcg/kg per minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For shock-refractory VF or pulseless VT: 1 mg/kg initially, followed by maintenance infusion of 20–50 mcg/kg per minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;402&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If time between initial bolus dose and onset of IV infusion &gt;15 minutes, repeat bolus dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;402&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Optimal dose not established, but usually 2–2.5 times the recommended IV dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usual initial dose is 50–100 mg administered as a direct IV injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;500&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If desired response is not achieved, a second dose may be administered 5 minutes after completion of the first injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;500&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For hemodynamically stable monomorphic VT: AHA recommends initial dose of 1–1.5 mg/kg, followed by 0.5–0.75 mg/kg repeated at 5- to 10-minute intervals as necessary, up to a maximum total dose of 3 mg/kg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For refractory VF or pulseless VT: 1–1.5 mg/kg as initial loading dose, then 0.5–0.75 mg/kg repeated at 5- to 10-minute intervals as necessary, up to a total of 3 doses (or up to 3 mg/kg).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Optimal dose not established, but usually 2–2.5 times the recommended IV dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initially, 1 mg/kg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; After 2 minutes, administer 0.5 mg/kg if seizure is not terminated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Maintenance infusion of 30 mcg/kg per minute for prevention of seizure recurrence.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Maximum total dose of 200–300 mg over a 1-hour period.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;100&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>Careful and individualized dosing recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;107&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;108&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;109&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;110&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;113&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage modification not required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Smaller bolus doses may be required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some clinicians recommend infusion rates &lt;30 mcg/kg per minute in patients with CHF.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible increased half-life following infusions lasting&gt;24 hours; reduce dosage accordingly (e.g., by 50%) to avoid accumulation of the drug and potential toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Lidocaine (Systemic)</h2><h3>Contraindications</h3><ul>
<li>
<p>Adams-Stokes syndrome; severe degrees of SA, AV, or intraventricular heart block (unless a functioning pacemaker is present).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Some manufacturers state that lidocaine is contraindicated in patients with Wolff-Parkinson-White syndrome.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Known hypersensitivity to amide-type local anesthetics.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Adams-Stokes syndrome; severe degrees of SA, AV, or intraventricular heart block (unless a functioning pacemaker is present).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Some manufacturers state that lidocaine is contraindicated in patients with Wolff-Parkinson-White syndrome.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Known hypersensitivity to amide-type local anesthetics.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Constant ECG monitoring is necessary during IV administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue infusion if signs of excessive cardiac depression occur (e.g., prolongation of PR interval and QRS complex, appearance or aggravation of arrhythmias).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Resuscitative equipment and drugs should be immediately available for the management of severe adverse cardiovascular, respiratory, or CNS effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue therapy if severe reactions occur; institute emergency resuscitative procedures and other supportive measures as required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe reactions may be preceded by somnolence and paresthesia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible hypersensitivity reactions (e.g., skin lesions, urticaria, edema, anaphylactoid reactions).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible increased half-life following infusions lasting &gt;24 hours; reduce dosage accordingly (see Patients Requiring Prolonged Therapy under Dosage and Administration).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If maintenance therapy is necessary, an oral antiarrhythmic agent is recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible muscle twitching or tremors, seizures, unconsciousness, and coma;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; may be associated with high doses or overdosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible hypotension, arrhythmias, heart block, cardiovascular collapse, and bradycardia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; which may lead to cardiac arrest in patients with high plasma lidocaine concentrations or myocardial conduction defects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible serious ventricular arrhythmias or heart block in patients with sinus bradycardia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible increased sensitivity to cardiac depressant effects in patients with a diseased or abnormal sinus node.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible increased ventricular rate in patients with atrial fibrillation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible increased coronary blood flow in patients with recent MI.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible myocardial and circulatory depression.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Cautious use recommended in patients with any form of heart block, CHF, marked hypoxia, severe respiratory depression, hypovolemia, or shock.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible respiratory depression and arrest;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; may be associated with high doses or overdosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible local thrombophlebitis in patients receiving prolonged IV infusions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Tissue infiltration may lead to local ischemia, tissue injury, and ulceration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible increased serum CK (CPK) concentrations associated with IM injections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Isoenzyme separation is necessary when CK determinations are used in the diagnosis of acute MI.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category B.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;117&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with caution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;100&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy not established in controlled clinical studies;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;100&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; however, lidocaine has been used for treatment of ventricular arrhythmias in infants and children.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;402&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;403&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Pharmacokinetics and also see Hepatic Impairment under Dosage and Administration.)</p><p>Use with caution in severe renal impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Elimination: Special Populations, under Pharmacokinetics.)</p><h3>Common Adverse Effects</h3><p>Adverse CNS effects (e.g., drowsiness, dizziness, disorientation, confusion, lightheadedness, tremulousness, psychosis, nervousness, apprehension, agitation, euphoria, tinnitus, visual disturbances, paresthesia, difficulty swallowing, dyspnea, slurred speech, sensations of heat, cold, or numbness), nausea, vomiting.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Lidocaine (Systemic)</h2><h3>Antiarrhythmic Agents</h3><p>Potential pharmacologic interaction (additive or antagonistic cardiac effects and additive toxicity) with concomitant administration of antiarrhythmic agents (e.g., phenytoin, procainamide, propranolol, quinidine).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Cimetidine</p><p>Decreased lidocaine clearance&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor serum lidocaine concentrations and observe closely for signs of lidocaine toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Phenytoin</p><p>Possible increased lidocaine metabolism&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Clinical importance unknown&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Propranolol</p><p>Decreased lidocaine clearance&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor serum lidocaine concentrations and observe closely for signs of lidocaine toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Succinylcholine</p><p>Increased neuromuscular blocking effect&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Appears to be important only at lidocaine doses higher than those used clinically&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Lidocaine (Systemic) Pharmacokinetics</h2><h3>Absorption</h3><p>Absorbed from the GI tract, but passes into hepatic circulation and only about 35% of an oral dose reaches the systemic circulation unchanged.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Toxic effects appear at oral doses that fail to produce therapeutic plasma concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following IM (deltoid) injection, peak plasma concentrations are achieved in 10 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Absorbed in trachea; when administered endotracheally, plasma concentrations generally lower than those achieved with vascular administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;458&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Absorption is biphasic.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;458&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Endotracheal absorption may be increased by diluting the drug in sterile water instead of 0.9% sodium chloride injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;401&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following direct IV (bolus) administration of 50–100 mg, onset of action is 45–90 seconds.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following direct IV (bolus) administration of 50–100 mg, duration is 10–20 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Plasma lidocaine concentrations of 1–5 mcg/mL are required to suppress ventricular arrhythmias; concentrations exceeding 5 mcg/mL associated with toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Widely distributed into body tissues.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Readily crosses the blood-brain barrier.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;117&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Crosses the placenta and is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;117&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Early, rapid decline in plasma concentrations is associated with distribution into highly perfused tissues (e.g., kidneys, lungs, liver, heart);&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; slower elimination phase associated with metabolism and redistribution into skeletal muscle and adipose tissue.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Binding is variable and concentration dependent;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;100&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;102&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;104&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; 60 –80% bound to plasma proteins at concentrations of 1–4 mcg/mL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;100&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;102&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;104&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Partially bound to α<sub>1</sub>-acid glycoprotein.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;100&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;102&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;104&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Volume of distribution is decreased in patients with CHF and increased in patients with liver disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Approximately 90% of a parenteral dose is metabolized rapidly in the liver by de-ethylation to the active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Rate of metabolism appears to be limited by hepatic blood flow.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Excreted in urine principally as metabolites.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Lidocaine has an initial half-life of 7–30 minutes and a terminal half-life of 1.5–2 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Elimination half-lives of MEGX and GX are 2 and 10 hours, respectively.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Rate of metabolism of lidocaine may be decreased and the half-life increased in patients with liver disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Major differences may exist in pharmacokinetics for different types of liver disease (e.g., cirrhosis, hepatitis); no consistent correlation established between clearance and severity of liver disease (as determined by liver function tests).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;107&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;108&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;109&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;110&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;113&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>GX may accumulate in patients with renal failure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In patients with MI, the half-lives of lidocaine and its metabolites appear to be prolonged.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In patients with CHF, half-life of lidocaine may be prolonged.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In individuals receiving continuous IV infusions lasting &gt;24 hours, half-life of lidocaine may be prolonged.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>25°C; may be exposed briefly to temperatures up to 40°C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not freeze; protect from excessive heat.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Extemporaneously prepared solutions (1–4 mg/mL in 5% dextrose injection) appear to be stable at room temperature for at least 24 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Compatible</p><p>Amino acids 4.25%, dextrose 25%</p><p>Dextrose 5% in Ringer’s injection, lactated</p><p>Dextrose 5% in sodium chloride 0.45 or 0.9%</p><p>Dextrose 5% in water</p><p>Ringer’s injection, lactated</p><p>Sodium chloride 0.45 or 0.9%</p><p>Drugs that require low pH for stability (e.g., dopamine, epinephrine, norepinephrine, isoproterenol) may be adversely affected by the pH of lidocaine (5–7).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use such mixtures promptly after preparation or consider separate administration of the drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; The manufacturers state that commercially available solutions of lidocaine hydrochloride in 5% dextrose should not be mixed with other drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Compatible</p><p>Alteplase</p><p>Aminophylline</p><p>Amiodarone HCl</p><p>Atracurium besylate</p><p>Calcium chloride</p><p>Calcium gluconate</p><p>Chloramphenicol sodium succinate</p><p>Chlorothiazide sodium</p><p>Ciprofloxacin</p><p>Dexamethasone sodium phosphate</p><p>Digoxin</p><p>Diphenhydramine HCl</p><p>Dobutamine HCl</p><p>Dopamine HCl</p><p>Ephedrine sulfate</p><p>Erythromycin lactobionate</p><p>Flumazenil</p><p>Furosemide</p><p>Heparin sodium</p><p>Hydrocortisone sodium succinate</p><p>Hydroxyzine HCl</p><p>Nafcillin sodium</p><p>Nitroglycerin</p><p>Penicillin G potassium</p><p>Pentobarbital sodium</p><p>Phenylephrine HCl</p><p>Potassium chloride</p><p>Procainamide HCl</p><p>Prochlorperazine edisylate</p><p>Ranitidine HCl</p><p>Sodium bicarbonate</p><p>Sodium lactate</p><p>Theophylline</p><p>Verapamil HCl</p><p>Incompatible</p><p>Methohexital sodium</p><p>Phenytoin sodium</p><p>Variable</p><p>Fentanyl citrate</p><p>Compatible</p><p>Alteplase</p><p>Amiodarone HCl</p><p>Argatroban</p><p>Bivalirudin</p><p>Cefazolin sodium</p><p>Ceftaroline fosamil</p><p>Ciprofloxacin</p><p>Cisatracurium besylate</p><p>Clarithromycin</p><p>Daptomycin</p><p>Dexmedetomidine HCl</p><p>Diltiazem HCl</p><p>Dobutamine HCl</p><p>Dobutamine HCl with dopamine HCl</p><p>Dobutamine HCl with nitroglycerin</p><p>Dobutamine HCl with sodium nitroprusside</p><p>Dopamine HCl</p><p>Dopamine HCl with dobutamine HCl</p><p>Dopamine HCl with nitroglycerin</p><p>Dopamine HCl with sodium nitroprusside</p><p>Enalaprilat</p><p>Etomidate</p><p>Famotidine</p><p>Fenoldopam mesylate</p><p>Haloperidol lactate</p><p>Heparin sodium</p><p>Heparin sodium with hydrocortisone sodium succinate</p><p>Hetastarch in lactated electrolyte injection (Hextend)</p><p>Labetalol HCl</p><p>Levofloxacin</p><p>Linezolid</p><p>Meperidine HCl</p><p>Micafungin sodium</p><p>Morphine sulfate</p><p>Nicardipine HCl</p><p>Nitroglycerin</p><p>Nitroglycerin with dobutamine HCl</p><p>Nitroglycerin with dopamine HCl</p><p>Nitroglycerin with sodium nitroprusside</p><p>Palonosetron HCl</p><p>Potassium chloride</p><p>Propofol</p><p>Remifentanil HCl</p><p>Sodium nitroprusside</p><p>Sodium nitroprusside with dobutamine HCl</p><p>Sodium nitroprusside with dopamine HCl</p><p>Sodium nitroprusside with nitroglycerin</p><p>Theophylline</p><p>Tigecycline</p><p>Tirofiban HCl</p><p>Vasopressin</p><p>Warfarin sodium</p><p>Incompatible</p><p>Amphotericin B cholesteryl sulfate complex</p><p>Metoprolol tartrate</p><h2>Actions</h2><ul>
<li>
<p>Membrane-stabilizing antiarrhythmic agent.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Combines with fast sodium channels in their inactive state and inhibits recovery after repolarization in a time- and voltage-dependent manner.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Exhibits rapid rates of attachment to and dissociation from transmembrane sodium channels.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Controls ventricular arrhythmias by suppressing automaticity in His-Purkinje system and by suppressing spontaneous depolarization of the ventricles during diastole.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Little effect on AV node conduction and His-Purkinje conduction in normal heart at therapeutic concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Affects conducting tissues of ventricles more than atria.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Variable effect on the effective refractory period (ERP) of the AV node; ERP and action potential duration of the His-Purkinje system are shortened.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Cardiac actions appear to be similar to those of phenytoin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>CNS depressant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Produces sedative, analgesic, and anticonvulsant effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Suppresses cough and gag reflexes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Produces little effect on autonomic tone; generally does not produce a substantial fall in BP, decreased myocardial contractility, or diminished cardiac output.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usually has little effect on heart rate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Membrane-stabilizing antiarrhythmic agent.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Combines with fast sodium channels in their inactive state and inhibits recovery after repolarization in a time- and voltage-dependent manner.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Exhibits rapid rates of attachment to and dissociation from transmembrane sodium channels.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Controls ventricular arrhythmias by suppressing automaticity in His-Purkinje system and by suppressing spontaneous depolarization of the ventricles during diastole.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Little effect on AV node conduction and His-Purkinje conduction in normal heart at therapeutic concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Affects conducting tissues of ventricles more than atria.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Variable effect on the effective refractory period (ERP) of the AV node; ERP and action potential duration of the His-Purkinje system are shortened.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Cardiac actions appear to be similar to those of phenytoin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>CNS depressant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Produces sedative, analgesic, and anticonvulsant effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Suppresses cough and gag reflexes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Produces little effect on autonomic tone; generally does not produce a substantial fall in BP, decreased myocardial contractility, or diminished cardiac output.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usually has little effect on heart rate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, and of concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, and of concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection, for direct IV injection</p><p>10 mg/mL*</p><p>Lidocaine Hydrochloride Injection for Cardiac Arrhythmias</p><p>20 mg/mL*</p><p>Lidocaine Hydrochloride Injection for Cardiac Arrhythmias</p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection, for IV infusion</p><p>4 mg/mL (1 or 2 g) Lidocaine Hydrochloride in 5% Dextrose*</p><p>0.4% Lidocaine Hydrochloride and 5% Dextrose Injection</p><p>8 mg/mL (2 or 4 g) Lidocaine Hydrochloride in 5% Dextrose*</p><p>0.8% Lidocaine Hydrochloride and 5% Dextrose Injection</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions October 30, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>Only references cited for selected revisions after 1984 are available electronically.</p><p>32. Thomson PD, Melmon KL, Richardson JA et al. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. <i>Ann Intern Med</i>. 1973; 78:499-508. http://www.ncbi.nlm.nih.gov/pubmed/4694036?dopt=AbstractPlus</p><p>52. Anon. Lignocaine for acute ventricular arrhythmias. <i>Drug Ther Bull</i>. 1969; 7:5-6. http://www.ncbi.nlm.nih.gov/pubmed/5763260?dopt=AbstractPlus</p><p>100. Astra Pharmaceutical Products, Inc. Xylocaine<sup></sup> (lidocaine hydrochloride) solution for ventricular arrhythmias prescribing information. Westborough, MA; 1997 Jun.</p><p>101. Tucker GT, Boyes RN, Bridenbaugh PO et al. Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physiochemical properties and anesthetic activity. <i>Anesthesiology</i>. 1970; 33:287-303. http://www.ncbi.nlm.nih.gov/pubmed/5454949?dopt=AbstractPlus</p><p>102. Routledge PA, Barchowsky A, Bjornsson TD et al. Lidocaine plasma protein binding. <i>Clin Pharmacol Ther</i>. 1980; 27:347-51. http://www.ncbi.nlm.nih.gov/pubmed/7357791?dopt=AbstractPlus</p><p>103. Routledge PA, Stargel WW, Wagner GS et al. Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. <i>Ann Intern Med</i>. 1980; 93:701-4. http://www.ncbi.nlm.nih.gov/pubmed/7212479?dopt=AbstractPlus</p><p>104. Routledge PA, Shand DG, Barchowsky A et al. Relationship between α<sub>1</sub>-acid glycoprotein and lidocaine disposition in myocardial infarction. <i>Clin Pharmacol Ther</i>. 1981; 30:154-7. http://www.ncbi.nlm.nih.gov/pubmed/7249498?dopt=AbstractPlus</p><p>105. Shand DG. α<sub>1</sub>-Acid glycoprotein and plasma lidocaine binding. <i>Clin Pharmacokinet</i>. 1984; 9(Suppl 1):27-31. http://www.ncbi.nlm.nih.gov/pubmed/6705424?dopt=AbstractPlus</p><p>106. Standards and Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiac Care (ECC). <i>JAMA</i>. 1986; 255:2905-84.</p><p>107. Forrest JAH, Finlayson NDC, Adjepon-Yamoah KK et al. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. <i>Br Med J</i>. 1977; 1:1384-7. http://www.ncbi.nlm.nih.gov/pubmed/861646?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1606933&amp;blobtype=pdf</p><p>108. Williams RL, Blaschke TF, Meffin PJ et al. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green. <i>Clin Pharmacol Ther</i>. 1976; 20:290-9. http://www.ncbi.nlm.nih.gov/pubmed/954351?dopt=AbstractPlus</p><p>109. Selden R, Sasahara AA. Central nervous system toxicity induced by lidocaine: report of a case in a patient with liver disease. <i>JAMA</i>. 1967; 202:908-9. http://www.ncbi.nlm.nih.gov/pubmed/6072663?dopt=AbstractPlus</p><p>110. Waller ES. Pharmacokinetic principles of lidocaine dosing in relation to disease state. <i>J Clin Pharmacol</i>. 1981; 21:181-94. http://www.ncbi.nlm.nih.gov/pubmed/7240439?dopt=AbstractPlus</p><p>111. Williams RL. Drug administration in hepatic disease. <i>N Engl J Med</i>. 1983; 309:1616-22. http://www.ncbi.nlm.nih.gov/pubmed/6358891?dopt=AbstractPlus</p><p>112. Rodman JH. Lidocaine. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. San Francisco: Applied Therapeutics, Inc; 1980:350-91.</p><p>113. Pomier-Layrargues G, Huet PM, Villeneuve JP et al. Effect of portacaval shunt on drug disposition in patients with cirrhosis. <i>Gastroenterology</i>. 1986; 91:163-7. http://www.ncbi.nlm.nih.gov/pubmed/3710065?dopt=AbstractPlus</p><p>114. Villeneuve JP, Thibeault MJ, Ampelas M et al. Drug disposition in patients with HBsAg-positive chronic liver disease. <i>Dig Dis Sci</i>. 1987; 32:710-4. http://www.ncbi.nlm.nih.gov/pubmed/3595383?dopt=AbstractPlus</p><p>115. Adjepon-Yamoah KK, Nimmo J, Prescott LF. Gross impairment of hepatic drug metabolism in a patient with chronic liver disease. <i>Br Med J</i>. 1974; 4:387-8. http://www.ncbi.nlm.nih.gov/pubmed/4425889?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1612505&amp;blobtype=pdf</p><p>116. Huet PM, Lelorier J. Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics. <i>Clin Pharmacol Ther</i>. 1980; 28:208-15. http://www.ncbi.nlm.nih.gov/pubmed/7398188?dopt=AbstractPlus</p><p>117. Zeisler JA, Gaarder TD, De Mesquita SA. Lidocaine excretion in breast milk. <i>Drug Intell Clin Pharm</i>. 1986; 20:691-3. http://www.ncbi.nlm.nih.gov/pubmed/3757781?dopt=AbstractPlus</p><p>118. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction.). <i>Circulation</i>. 1990; 82:664-707. http://www.ncbi.nlm.nih.gov/pubmed/2197021?dopt=AbstractPlus</p><p>119. MacMahon S, Collins R, Peto R et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. <i>JAMA</i>. 1988; 260:1910-6. http://www.ncbi.nlm.nih.gov/pubmed/3047448?dopt=AbstractPlus</p><p>120. Davison R, Parker M, Atkinson AJ Jr. Excessive serum lidocaine levels during maintenance infusions: mechanisms and prevention. <i>Am Heart J</i>. 1982; 104:203-8. http://www.ncbi.nlm.nih.gov/pubmed/7102503?dopt=AbstractPlus</p><p>125. Landers MD, Reiter MJ. General principles of antiarrhythmic therapy for ventricular tachyarrhythmias. <i>Am J Cardiol</i>. 1997; 80(Suppl 8A):31-44G.</p><p>126. Tan HL, Lie KI. Prophylactic lidocaine use in acute myocardial infarction revisited in the thrombolytic era. <i>Am Heart J</i>. 1999; 137:770-3. http://www.ncbi.nlm.nih.gov/pubmed/10220620?dopt=AbstractPlus</p><p>127. Dorian P, Cass D, Schwartz B et al. Amiodarone as compared with lidocaine for shock-Resistant ventricular fibrillation. <i>N Engl J Med</i>. 2002; 346:884-890. http://www.ncbi.nlm.nih.gov/pubmed/11907287?dopt=AbstractPlus</p><p>128. The American Heart Association. Guidelines 2005 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2005; 112(Suppl I): IV1-211.</p><p>129. Eigel B. (American Heart Association, Dallas, TX): Personal communication; 2006 April 27.</p><p>130. Eigel B. (American Heart Association, Dallas, TX): Personal communication; 2006 May 3.</p><p>300. Page RL, Joglar JA, Caldwell MA et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016; 67:e27-e115.</p><p>301. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2014; 64:e1-76. http://www.ncbi.nlm.nih.gov/pubmed/24685669?dopt=AbstractPlus</p><p>400. Link MS, Berkow LC, Kudenchuk PJ et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015; 132(18 Suppl 2):S444-64. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=4771073&amp;blobtype=pdf</p><p>401. Neumar RW, Otto CW, Link MS et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010; 122(18 Suppl 3):S729-67.</p><p>402. de Caen AR, Berg MD, Chameides L et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015; 132(18 Suppl 2):S526-42. http://www.ncbi.nlm.nih.gov/pubmed/26473000?dopt=AbstractPlus</p><p>403. Kleinman ME, Chameides L, Schexnayder SM et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010; 122(18 Suppl 3):S876-908. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=3717258&amp;blobtype=pdf</p><p>458. Prengel AW, Lindner KH, Hähnel JH et al. Pharmacokinetics and technique of endotracheal and deep endobronchial lidocaine administration. <i>Anesth Analg</i>. 1993; 77:985-9. http://www.ncbi.nlm.nih.gov/pubmed/8214738?dopt=AbstractPlus</p><p>459. Valdes SO, Donoghue AJ, Hoyme DB et al. Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. <i>Resuscitation</i>. 2014; 85:381-6. http://www.ncbi.nlm.nih.gov/pubmed/24361455?dopt=AbstractPlus</p><p>500. APP Pharmaceuticals. Xylocaine<sup></sup> (lidocaine hydrochloride) solution for ventricular arrhythmias prescribing information. Schaumburg, IL; 2011 May.</p><p>527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013; 127:e362-425. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=3695607&amp;blobtype=pdf</p><p>a. AHFS Drug Information 2018. McEvoy GK, ed. Lidocaine Hydrochloride. Bethesda, MD: American Society of Health-System Pharmacists; 2018.</p><p>b. Baxter Healthcare Corporation. Lidocaine hydrochloride and 5% Dextrose Injection, USP prescribing information. Deerfield, IL; 1998 Jul.</p><p>HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013: 700-8.</p><h2>More about lidocaine</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>11 Reviews</li>
<li>Drug class: group I antiarrhythmics</li>
<li>FDA Alerts (7)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lidocaine Injection &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Lidocaine Intradermal &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Lidocaine (Systemic) &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Professional Patient Advice)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Lidocaine &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Lidocaine Injection &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Lidocaine Intradermal Injection &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Anesthesia</li>
<li>Arrhythmia</li>
<li>Costochondritis</li>
<li>Burning Mouth Syndrome</li>
<li>Ventricular Fibrillation</li>
<li>Ventricular Tachycardia</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>